Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial

Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)

(2010) Brian L. Strom et al.   AMERICAN JOURNAL OF PSYCHIATRY

Absence of weight gain association with the HTR2C −759C/T polymorphism in patients with schizophrenia treated with iloperidone

(2010) Andrew Thompson et al.   PSYCHIATRY RESEARCH

A 28-Week, Randomized, Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia

(2009) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHIATRY

A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia

(2008) W. Wolfgang Fleischhacker et al.   BIOLOGICAL PSYCHIATRY

Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia

(2008) Andrew J. Cutler et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Long-Term Efficacy and Safety of Iloperidone

(2008) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Safety Profile of Iloperidone

(2008) Peter J. Weiden et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Efficacy of Iloperidone in the Treatment of Schizophrenia

(2008) Steven G. Potkin et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY